Tüdőrák: nyitott vizsgálatok itt: Hollandia
142 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Arnhem, Heerlen, Leiden
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386EU 2024-513682-40-01Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Amersfoort, Groningen, Leeuwarden, Maastricht, Nijmegen, 'S-Hertogenbosch, Zwolle
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422EU 2023-506327-29-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Amersfoort, Amsterdam, Groningen, Harderwijk, Leeuwarden, Nijmegen, Tilburg, Zwolle
- Age
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376EU 2025-522643-18-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Geleen, 'S-Hertogenbosch
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170EU 2025-524263-21-01Regiszter frissítve: 2026-11-09
1/2. fázisToborozTrial-stage medicine
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Amsterdam, Groningen
- Age
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626EU 2024-514266-39-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Amersfoort, Groningen, Harderwijk, Maastricht, Nijmegen, Tilburg, Zwolle
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- Where
- Amsterdam, Utrecht
- Age
- 18 év and over
- People
- 290 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317EU 2023-508773-82-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Amsterdam, Groningen, Maastricht, Nijmegen, Rotterdam
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784EU 2024-518154-16-00Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Amsterdam, Nijmegen
- Age
- 18 év and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082EU 2023-507171-22-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Amersfoort, Amsterdam, Arnhem, Breda, Harderwijk, Leidschendam, Zwolle
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Amsterdam, Maastricht, Rotterdam, Utrecht
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280EU 2025-521281-97-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Amsterdam, Breda, Groningen, Nijmegen, Zwolle
- Age
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497EU 2025-523576-23-00Regiszter frissítve: 2026-11-05
1. fázisToborozTrial-stage medicine
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Amsterdam
- Age
- 18 év and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Enschede, Harderwijk, Hilversum, Leeuwarden, Leiden, Rotterdam, 's-Hertogenbosch, Tilburg, Utrecht
- Age
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581EU 2023-503412-33-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Amsterdam
- Age
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277EU 2024-511319-91-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Amsterdam, Breda, Harderwijk, Maastricht, Tilburg, Utrecht, Zwolle
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598EU 2024-512302-25-00Regiszter frissítve: 2026-11-04
3. fázisToborozResearch participation
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
- Where
- Maastricht
- Age
- 18 év and over
- People
- 65 worldwide
- Run by
- Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00EU 2022-502959-54-00Regiszter frissítve: 2026-11-03
4. fázisToborozTrial-stage medicine
Dabrafenib and/or Trametinib Rollover Study
- Where
- Utrecht
- Age
- 18 év to 100 év
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506EU 2023-509318-13-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Breda, Tilburg, Zwolle
- Age
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788EU 2023-503376-24-00Regiszter frissítve: 2026-11-03
2. fázisToborozTrial-stage medicine
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Where
- Amsterdam, Nijmegen
- Age
- 18 év and over
- People
- 130 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908EU 2024-518276-32-00Regiszter frissítve: 2026-11-03
2. fázisToborozTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Age
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177EU 2025-522107-18-00Regiszter frissítve: 2026-11-03
2/3. fázisToborozTrial-stage medicine
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Leiden
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319EU 2025-525013-23-00Regiszter frissítve: 2026-11-03
2. fázisToborozResearch participation
OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boosting with cobicistat or ritonavir
- Where
- Amsterdam, Geleen, Groningen, Maastricht, Rotterdam
- Age
- 18 év and over
- People
- 51
- Run by
- University Hospital Maastricht
See details and how to joinNCT05748093EU 2023-505700-35-00Regiszter frissítve: 2026-11-02
3. fázisToborozTrial-stage medicine
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Amsterdam
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695EU 2025-521284-12-00Regiszter frissítve: 2026-11-02
3. fázisToborozTrial-stage medicine
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Almelo, Arnhem, Groningen, Leiden, Nijmegen
- Age
- 18 év and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339EU 2025-522038-29-00Regiszter frissítve: 2026-11-02
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.